SCHEMBL7204271

SCHEMBL7204271

COc1cccc(Oc2ccc(S(=O)(=O)C3CCN(C(N)=O)CC3(O)C(=O)O)cc2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 4/20 0.45
MMP13 P45452 4/20 0.45
MMP2 P08253 4/20 0.42
MMP9 P14780 4/20 0.42
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA9 Q16790 2/20 0.40
CA7 P43166 1/20 0.40
CA14 Q9ULX7 1/20 0.40
MTNR1A P48039 1/20 0.40
MTNR1B P49286 1/20 0.40
PARP10 Q53GL7 5/20 0.39
PARP14 Q460N5 3/20 0.39
MMP3 P08254 3/20 0.39
MMP14 P50281 2/20 0.39
MMP12 P39900 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MMP10 P09238 1/20 0.39
PGR P06401 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7203058 0.92 MMP9 (0.47) MMP1MMP13MMP2MMP9CA12
SCHEMBL7205634 0.91 MMP13 (0.55) MMP1MMP13MMP2MMP9PARP10
SCHEMBL7207163 0.90 MMP1 (0.45) MMP1MMP13MMP2MMP9PARP10
SCHEMBL7199646 0.89 MMP1 (0.43) MMP1MMP13MMP2MMP9PARP10
SCHEMBL7207978 0.89 PARP10 (0.45) MMP1MMP13MMP2MMP9PARP10
SCHEMBL7201767 0.89 NAAA (0.44) MMP13CA12CA1CA2CA9
SCHEMBL7201220 0.87 MMP1 (0.47) MMP1MMP13MMP2MMP9MMP14
SCHEMBL7206530 0.87 TSHR (0.45) MMP1MMP13MMP2MMP9MMP3
SCHEMBL7204562 0.86 MMP13 (0.51) MMP1MMP13MMP2MMP9MMP3
SCHEMBL7205455 0.86 MMP9 (0.44) MMP1MMP13MMP2MMP9MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 MMP1 8/4885MMP13 4/4885MMP2 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.